Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Patient characteristics of those receiving BTKi treatment
研究概览
简要总结
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years;
- •Patients with a confirmed diagnosis of CLL/SLL;
- •Received BTK inhibitor treatment between February 2023 and February 2024.
排除标准
- •Patients with other types of lymphoma;
- •Cases deemed unsuitable for inclusion in this study by the investigators.
研究组 & 干预措施
BTK inhibitor treated
investigate the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, including the efficacy and safety, the drug swith between different BTKis，the BTKi based timed limited therapy, etc
干预措施: BTK inhibitor (Drug)
结局指标
主要结局
Patient characteristics of those receiving BTKi treatment
时间窗: up to one year
Describe the patient characteristics of those receiving BTKi treatment, including age, gender, etc
次要结局
- overall response rate(up to one year)
- Incidence of adverse reactions(up to one year)